Comparative Pharmacology
Head-to-head clinical analysis: POTASSIUM IODIDE versus THYROSHIELD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POTASSIUM IODIDE versus THYROSHIELD.
POTASSIUM IODIDE vs THYROSHIELD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium iodide suppresses thyroid hormone synthesis and release via the Wolff-Chaikoff effect, inhibiting iodide organification and reducing vascularity of the thyroid gland.
Thyroshield (potassium iodide) acts by supplying excess iodide, which inhibits thyroid hormone synthesis via the Wolff-Chaikoff effect, blocks thyroidal iodide uptake, and reduces thyroid vascularity. It also protects the thyroid from radioactive iodine uptake by saturating iodine transport and organification mechanisms.
Oral: 300 mg (0.3 mL of saturated solution) three times daily for thyroid protection in radiation exposure; for hyperthyroidism preoperative: 60-250 mg (0.06-0.25 mL) three times daily.
Intravenous: Loading dose 200 mg, then 50 mg every 6 hours; or continuous infusion: 200 mg bolus then 800 mg over 24 hours. Oral: 50 mg every 6 hours.
None Documented
None Documented
Clinical Note
moderateWarfarin + Potassium Iodide
"Warfarin may decrease the anticoagulant activities of Potassium Iodide."
Clinical Note
moderatePhenprocoumon + Potassium Iodide
"Phenprocoumon may decrease the anticoagulant activities of Potassium Iodide."
Clinical Note
moderatePhenindione + Potassium Iodide
"Phenindione may decrease the anticoagulant activities of Potassium Iodide."
Clinical Note
moderateAcenocoumarol + Potassium Iodide
Terminal half-life in euthyroid individuals is approximately 13 days (range 10–15 days). In hyperthyroidism, half-life may be shortened to 5–6 days due to increased thyroid clearance; in hypothyroidism, half-life may be prolonged up to 40 days.
Terminal elimination half-life is 12-24 hours; clinical effect persists 24-36 hours after single dose.
Renal: >90% of absorbed iodide is excreted in urine; fecal elimination is negligible (<2%).
Primarily renal (90-95% unchanged), minor biliary/fecal (5-10%).
Category C
Category C
Antithyroid Agent
Antithyroid Agent
"Acenocoumarol may decrease the anticoagulant activities of Potassium Iodide."